Myeloablative, reduced toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients in the sixth through eighth decades of life
in press.
Alatrash G, de Lima M, Hamerschlak N, et al. Myeloablative, reduced toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients in the sixth through eighth decades of life. Biol Blood Marrow Transplant. in press.
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
Andersson B.S., de Lima M., Thall P.F., et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide
Bredeson C.N., Zhang M.J., Agovi M.A., et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:993-1003.
A risk score for mortality after allogeneic hematopoietic cell transplantation
Parimon T., Au D.H., Martin P.J., Chien J.W. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006, 144:407-414.
Hematopoietic cell transplantation (HCT)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT
Sorror M.L., Maris M.B., Storb R.F., et al. Hematopoietic cell transplantation (HCT)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT. Biol Blood Marrow Transplant 2005, 11(Suppl. 1):23-24.
Dose intensity of preparative regimens for acute myeloid leukemia-one-size-fits-all or tailor-made?
Appelbaum F.R. Dose intensity of preparative regimens for acute myeloid leukemia-one-size-fits-all or tailor-made?. Best Pract Res Clin Haematol 2010, 23:509-517.
Prediction of early death following induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
in press.
Walter RB, Othus M, Borthakur G, et al. Prediction of early death following induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. in press.
